NCT02922231View on ClinicalTrials.gov

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

CompletedOBSERVATIONAL
Enrollment

57

Participants

Timeline

Start Date

January 6, 2017

Primary Completion Date

April 4, 2019

Study Completion Date

April 4, 2019

Conditions
Hemophilia B
Interventions
BIOLOGICAL

RIXUBIS

Recombinant Factor IX (rFIX) for intravenous use

Trial Locations (5)

13316

Chung Hospital, Gyeonggi-do

35233

DaeJeon Eulji University Hospital, Daejeon

42472

Daegu Catholic University Medical Center, Daegu

05538

Kim Hugh Chul Internal Medicine, Seoul

06641

Korea Hemophilia Foundation, Seoul

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT02922231 - Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea | Biotech Hunter | Biotech Hunter